BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25790158)

  • 1. The current status in hematopoietic stem cell mobilization.
    Civriz Bozdag S; Tekgunduz E; Altuntas F
    J Clin Apher; 2015 Oct; 30(5):273-80. PubMed ID: 25790158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
    Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
    Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
    Uy GL; Rettig MP; Cashen AF
    Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.
    Larochelle A; Krouse A; Metzger M; Orlic D; Donahue RE; Fricker S; Bridger G; Dunbar CE; Hematti P
    Blood; 2006 May; 107(9):3772-8. PubMed ID: 16439684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.
    Jantunen E; Lemoli RM
    Transfusion; 2012 Apr; 52(4):906-14. PubMed ID: 21981351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous Stem Cell Mobilization in the Age of Plerixafor.
    Cooper DL; Medoff E; Patel N; Baker J; Pratt K; Foss F; Seropian SE; Perreault S; Wu Y
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):411-6. PubMed ID: 27245311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells.
    Ramirez P; Rettig MP; Uy GL; Deych E; Holt MS; Ritchey JK; DiPersio JF
    Blood; 2009 Aug; 114(7):1340-3. PubMed ID: 19571319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.
    Selleslag D; Dierickx D; Breems DA; Huynh P; Van De Velde A; Meers S; Brouwer E; Mertens A
    Acta Clin Belg; 2011; 66(3):200-4. PubMed ID: 21837928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
    Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic stem cell mobilization: a clinical protocol.
    Pesek G; Cottler-Fox M
    Methods Mol Biol; 2012; 904():69-77. PubMed ID: 22890922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor.
    Fadini GP; Fiala M; Cappellari R; Danna M; Park S; Poncina N; Menegazzo L; Albiero M; DiPersio J; Stockerl-Goldstein K; Avogaro A
    Diabetes; 2015 Aug; 64(8):2969-77. PubMed ID: 25804941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
    De Clercq E
    Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of mobilization failure in 2017.
    Namdaroglu S; Korkmaz S; Altuntas F
    Transfus Apher Sci; 2017 Dec; 56(6):836-844. PubMed ID: 29153350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIF-1α is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1α.
    Forristal CE; Nowlan B; Jacobsen RN; Barbier V; Walkinshaw G; Walkley CR; Winkler IG; Levesque JP
    Leukemia; 2015 Jun; 29(6):1366-78. PubMed ID: 25578474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
    Gattillo S; Marktel S; Rizzo L; Malato S; Malabarba L; Coppola M; Assanelli A; Milani R; De Freitas T; Corti C; Bellio L; Ciceri F
    Transfusion; 2015 Aug; 55(8):1993-2000. PubMed ID: 25721167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
    Maziarz RT; Nademanee AP; Micallef IN; Stiff PJ; Calandra G; Angell J; Dipersio JF; Bolwell BJ
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):670-5. PubMed ID: 23333777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.